Hmmmm....who said it? My ADT brain makes me forget. You have to understand the difference between real clinical trials and observational studies. When HCQ has been used in blind trials it has shown to not be effective. Multiple trials, thousands of patients.
In the mean time India goes right on with their 30 deaths per million while we go right on with our 483. The main difference? They use it, we don't. Do you have the links for " Multiple trials, thousands of patients", so that we can analyze them? Are these the same trials that had to be retracted? Did they start the drug when it was too late, since it is well know to work much better early on? Did any of them use zinc with it? Did they use a toxic dose, or did they use the typical dose that has been given to patients for Lupus or malaria for 50 years?
Finally, apparently the Henry Ford Health System study is not up to every one's standards? A very well respected research institution, with 30,000 employees and 1,900 physicians and researchers in more than 40 specialties. Giving 2500 people either hydroxychloroquine(HCQ)( lowest death rate, or 4th highest death rate), , or HCQ + zithromax( 3rd highest death rate), or zithromax only(2nd highest death rate), or none of the above(the highest death rate)? But, this is not useful evidence? And handicapped by, rather than giving it at the very first sign of the disease, when they first go to the doctor and are diagnosed, giving it after they are already hospitalized? Still deaths cut in half? Published today in the International Journal of Infectious Diseases, the peer-reviewed,
open-access online publication of the International Society of Infectious Diseases (ISID.org), not good enough? Because other studies are better and have proven this later study wrong? So no one wants the HCQ early on? ( I know several physicians who got it for themselves and took it prophylactally. Well, I need to see the details on the studies that show it to be useless or harmful. And I remember some of them have been retracted. I have a sneaking suspicion there are some major flaws or bias in those studies.
"In a large-scale retrospective analysis of 2,541 patients hospitalized between March 10 and May 2, 2020 across the system’s six hospitals, the study found 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with hydroxychloroquine. None of the patients had documented serious heart abnormalities;
however, patients were monitored for a heart condition routinely pointed to as a reason to avoid the drug as a treatment for COVID-19.......................The vast majority received the drug soon after admission; 82% within 24 hours and 91% within 48 hours of admission. All patients in the study were 18 or over with a median age of 64 years; 51% were men and 56% African American............................“The findings have been highly analyzed and peer-reviewed,” said Dr. Marcus Zervos, division head of Infectious Disease for Henry Ford Health System
, who co-authored the study with Henry Ford epidemiologist Samia Arshad. “We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring. Our dosing also differed from other studies not showing a benefit of the drug. And other studies are either not peer reviewed, have limited numbers of patients, different patient populations or other differences from our patients.”
Zervos said the potential for a surge in the fall or sooner, and infections continuing worldwide, show an urgency to identifying inexpensive and effective therapies and preventions.
“We’re glad to add to the scientific knowledge base on the role and how best to use therapies as we work around the world to provide insight,” he said. “Considered in the context of current studies on the use of hydroxychloroquine for COVID-19, our results suggest that the drug may have an important role to play in reducing COVID-19 mortality.” ................The study also found those treated with azithromycin alone or a combination of hydroxychloroquine and azithromycin also fared slightly better than those not treated with the drugs, according to the Henry Ford data. The analysis found 22.4% of those treated only with azithromycin died, and 20.1% treated with a combination of azithromycin and hydroxychloroquine died, compared to 26.4% of patients dying who were not treated with either medication.“Our analysis shows that using hydroxychloroquine helped save lives,” said neurosurgeon Dr. Steven Kalkanis, CEO, Henry Ford Medical Group and Senior Vice President and Chief Academic Officer of Henry Ford Health System. “As doctors and scientists, we look to the data for insight. And the data here is clear that there was benefit to using the drug as a treatment for sick, hospitalized patients.”
Henry Ford Health System, as one of the region’s major academic medical centers with more than $100 million in annual research funding, is involved in numerous COVID-19 trials with national and international partners.
Henry Ford Health System is currently also involved in a prophylactic hydroxychloroquine study: “Will Hydroxychloroquine Impede or Prevent COVID-19,” or WHIP COVID-19. The study is a 3,000-person, randomized, double-blinded look at whether hydroxychloroquine prevents healthcare and frontline workers from contracting the COVID-19 virus. The WHIP COVID-19 team is working on expanding study sites while there is a lull in the number of COVID-19 cases in Southeast Michigan. This is in preparation for a potential increase of COVID-19 cases as Fall flu season approaches, with additional sites available for convenient enrollment of healthcare workers and first responders. The WHIP COVID-19 team is also taking this gift of time to reach out to other areas of the world that are seeing a blossoming of cases: Brazil and Argentina. There are currently 619 people enrolled in the study, out of a target of 3,000.
Henry Ford Health System:
Under the leadership of President and CEO Wright L. Lassiter, III, Henry Ford Health System is a $6.5 billion integrated health system comprised of six hospitals, a health plan, and 250+ sites including medical centers, walk-in and urgent care clinics, pharmacy, eye care facilities and other healthcare retail. Established in 1915 by auto industry pioneer Henry Ford, the health system now has 32,000 employees and remains home to the 1,900-member Henry Ford Medical Group, one of the nation’s oldest physician groups. An additional 2,200 physicians are also affiliated with the health system through the Henry Ford Physician Network. An active participant in medical education and training, the health system has trained nearly 40% of physicians currently practicing in the state and also provides education and training for other health professionals including nurses, pharmacists, radiology and respiratory technicians.
Media contact email: MediaRelations@hfhs.org ".